hyLabs

hyLabs is Israel's leading developer, manufacturer and distributor of diagnostic solutions specializing in microbiology and molecular biology. For five decades, the company has been at the forefront of infection disease diagnostics, providing innovative tools for detection and identification of microorganisms. In May 2025, hyLabs acquired Progenetics, an Israeli pioneering company for precision oncology that specializes in advanced genetic testing for cancer patients and offers the widest range of oncology tests available in Israel. Progenetics collaborates with leading laboratories worldwide, works with all hospitals in Israel, and conducts thousands of tests annually adhering to international standards. hyLabs represents numerous international companies including HiMedia, Mast Group, SSI Diagnostica, Seegene, Crosstex, Romer Labs, ChromAgar, Hardy Diagnostics, Biolife, Azenta, DeNovix, BioHelix, Geneaid, and many others. The company serves multiple sectors including clinical diagnostics, academic research, pharmaceutical and biotech industries, cosmetic and food testing, and water analysis. Their services encompass advanced microbiology methods, molecular biology products, genetic medical laboratory services, disinfectant efficacy testing, and comprehensive diagnostic solutions. hyLabs operates GMP certified laboratories and maintains strong ties with the medical and research communities, actively participating in academic research and providing internship opportunities recognized by the Ministry of Health.